SPONSORSHIP ALLIANCE NEWS
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with disease progression on or after treatment with an EGFR-tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.
Investment Aims to Further Accelerate Manufacturing, Sales, and Distribution of the ZAP-X Gyroscopic Radiosurgery Platform
ZAP-X demonstrated potent anti-tumor efficacy and adequate tolerability and should be considered a new treatment option for relapsed refractory patients.
As the sponsor of the meeting, Vision RT announces that abstracts are open for the 2025 US SGRT Community Meeting, being held at the Grand Hyatt Hotel in downtown Denver, CO on June 4-6, 2025. This will be an opportunity to share best practices and network with peers in a venue surrounded by the majesty of the Rocky Mountains. We invite you to submit on any surface guidance topic through the Simulation, Planning, Treatment and Dose Visualization steps. Travel grants are available for successful submissions, and the abstract window will close on Monday, February 3, 2025. Attendance to this event will be completely FREE and 100% peer-driven, with all sessions and talks delivered by SGRT users. The three-day event will be made up of an on-site visit to an SGRT expert user center, presentations, workshops, and the latest innovations, as well as real-life case reports.
Smilow Cancer Hospital, from Yale New Haven Health, successfully delivered the world’s first radiotherapy treatment plan that combines different radiotherapy modalities to a patient with metastatic cancer on the RefleXion® X1. With Multi-target Treatment, the X1 platform integrates both SCINTIX® biology-guided radiotherapy and SBRT to treat multiple tumors in one single plan.
Susanne Kluh, a 57-year-old diagnosed with stage 4 non-small cell lung cancer, is grateful for breakthrough technologies like SCINTIX therapy. Following her therapy, she no longer experiences the pain caused from the tumors in her spine and is keen on sharing this new technology and its benefits with others. She is just one of the more than 30 patients treated with SCINTIX therapy since FDA clearance, with more receiving treatment every week. Listen to Susanne's interview, hear from her physician, Dr. Yufei Liu from City of Hope, and from Sam Mazin, our founder and CTO, as they describe this groundbreaking technology.
During ASTRO 2024, RefleXion showcased Multi-target Treatment (MTT), the groundbreaking X1 platform upgrade that allows physicians to combine SCINTIX® biology-guided radiotherapy with conventional stereotactic body radiotherapy (SBRT) in a single plan to treat patients with metastatic disease. Researchers also presented new scientific evidence in 22 presentations during this conference, including four oral presentations, showcasing the RefleXion® X1 machine with SCINTIX therapy.
Combining ZAP-X’s novel gyroscopic mechanics with continuous beam delivery, Dynamic Spherical Delivery is set to redefine SRS efficiency, dose gradient, and conformality. Transcending the innate mechanical shortcomings of multi-purpose radiotherapy systems, for the first time ever, continuous orthogonal beams, spirals, oblique spirals, or any combination become reality. The goal: better treatments in less time.
Finally, non-invasively treat brain tumors. Anywhere. Everywhere. In this on-demand presentation, peer physicians share their knowledge and experience in building high-volume ZAP-X SRS programs. Additionally, discover how others have expanded patient access to SRS with ZAP-X installation sites that were previously inconceivable, yet now more convenient and lower cost. Watch the presentation here.
AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy (CRT). Tagrisso is indicated for patients with exon 19 deletions or exon 21 (L858R) mutations, as detected by a FDA-approved test.
Prostate cancer is a major health concern. One in eight men will be diagnosed with prostate cancer at some point in their life. Other than skin cancer, it is the most common form of cancer in men—the American Cancer Society estimates there will be nearly 300,000 new cases of prostate cancer this year in the U.S.—and it is the second-deadliest behind lung cancer. The American Cancer Society, though, does report some good news: From 1993 to 2013, prostate cancer's death rate was cut in half likely due to earlier detection and treatment advances.
To spotlight the country's top prostate cancer specialists, Newsweek is partnering with Statista for the first annual ranking of America's Best Prostate Cancer Oncologists & Surgeons. The ranking recognizes the top 150 individuals in each of the two categories.
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to standard-of-care chemotherapy improved progression-free survival (PFS) in patients with oligometastatic pancreatic cancer. Findings from the multicenter EXTEND trial, published today in the Journal of Clinical Oncology, were first presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.